Bionor Pharma ASA

Type: Company

Name: Bionor Pharma ASA

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Annual General Meeting Strengthens the Board of Directors with Financial and Regulatory Competencies

- Bionor Pharma's shareholders appointed Algeta's CFO, Øystein Soug, and Ferring's Senior Vice President of Regulatory Affairs, Marianne Kock to the Board of Directors at the Annual General Meeting."We have today added extensive competence from the financial ... [Published Reuters - May 15 2013]

Entities: Algeta ASA, Bionor Pharma ASA, Ferring Pharmaceuticals

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Bionor Pharma Reports Strengthening and Consolidation of Organization

) Bionor Pharma ASA (OSE:BIONOR) today announced financial results for first quarter 2013, $ and provided highlights of key operational developments during first quarter 2013, current status and outlook.Webcast The Q1 report will be presented by webcast ... [Published Reuters - May 15 2013]

Entities: Bionor Pharma ASA, Teleconference, Phase I/II, Nutraceuticals, HIV/AIDS

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Pronova BioPharma ASA

Synne H Røine, new Chief Financial Officer Begins at Bionor Pharma Medio May

The Appointment Strengthens Bionor Pharma's Management Team and Presence in the Financial Market$ $ (Oslo, Norway 14 May 2013)$ Bionor Pharma ASA (OSE: BIONOR) today announced that Synne H Røine, who was announced 1 March as the Company's new CFO, now ... [Published EuroInvestor - May 14 2013]

Entities: Bionor Pharma ASA, Pronova BioPharma ASA, Norwegian Securities Trading Act, BASF SE

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Bionor Pharma Presenting Q1 2013 Interim Report by Webcast Wednesday 15 May at 8.30 am CEST

) Bionor Pharma ASA (OSE:BIONOR) will announce its Q1 2013 interim report Wednesday 15 May 2013 at 8.30.We are pleased to invite you to join in on our international webcast (and teleconference) for analysts, investors and other stakeholders at 08.30 CEST ... [Published Reuters - May 07 2013]

Entities: Bionor Pharma ASA, Teleconference, Denmark, Norway

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Last Patient Enrolled in Bionor Pharma's International Study to Reboost Patients from the Completed Vacc-4x Phase II Clinical Trial.

Thirty-three Patients Participate at 10 Clinics in USA and Europe(Oslo, 29 April 2013)$ Bionor Pharma ASA (OSE: BIONOR) announced today that all patients are now enrolled in the study for reboost of patients from the previously conducted phase II clinical ... [Published Reuters - Apr 29 2013]

Entities: HIV/AIDS, Bionor Pharma ASA, Patient, Vaccine

Quotes

..." said Lars H Høie, MD, PhD, Chairman, Board of Directors, Bionor Pharma.$ "We are confident that the new Directors will contribute significantly with relevant knowhow to strengthen the leadership that will help guide the Company through the exciting phases of development ahead of us."

Annual General Meeting Strengthens the Board of Directors with Financial and Regulatory Competencies [Published Reuters - May 15 2013]